CROSSJECT strengthens its governance for the industrial and commercial deployment phase

DIJON, FRANCE, September 25, 2026 — 07h30 (CEST) — CROSSJECT (ISIN: FR0011716265; Euronext Growth: ALCJ), a Specialty Pharma company developing innovative solutions for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, today announces that its Supervisory Bo…